• Jeffrey Henderson will joinCardinal Health(Dublin, Ohio) as executive vice president and CFO, succeeding interim CFO J. Michael Losh. Henderson most recently was president and general manager of Eli Lilly Canada and previously vice president and corporate controller of Eli Lilly & Co. He will join Cardinal Health on April 18 to work with Losh before assuming the CFO position on May 15. Losh will remain on the company’s board of directors. Losh, who retired as CFO of General Motors, has served in his interim role since last July. Cardinal Health is a major provider of healthcare products and services.

• James Mulry has been named director of marketing, hematology for Clinical Data (Newton, Massachusetts). Prior to joining Clinical Data, Mulry was vice president of sales and marketing at ABX Diagnostics. Clinical Data, through its subsidiaries, provides a complete range of products and consulting services to the physician’s office laboratory market and offers blood chemistry instrumentation and diagnostic assays to clinics and small hospitals throughout the world.

• Richard Lanman, MD, was appointed executive vice president and chief medical officer of diaDexus (South San Francisco, California). Prior to joining diaDexus, Lanman served as executive vice president, corporate business development, and chief medical officer at Atherotech. Lanman also was founder, chairman and CEO of Adesso Healthcare Technology Services. diaDexus, a privately held biotechnology company, is focused on the development of new diagnostic and therapeutic products with high clinical value.

• Martin Schmieg has been named senior vice president and CFO of Isolagen (Exton, Pennsylvania). Schmieg most recently served as senior vice president and CFO of Sirna Therapeutics. Isolagen specializes in the development of autologous cellular therapies for soft and hard tissue regeneration. The company’s product candidates are based on its Isolagen Process and are directed toward dermatology, gum disease, vocal cord lesions, and wound treatment.